2019
DOI: 10.1055/a-1027-6472
|View full text |Cite
|
Sign up to set email alerts
|

Primary and Secondary Hyperparathyroidism in Patients with Primary Aldosteronism – Findings From the German Conn’s Registry

Abstract: Context Recent studies support a bidirectional interaction between aldosterone and parathyroid hormone (PTH), possibly increasing the individual cardiovascular risk. Primary aldosteronism (PA) and primary hyperparathyroidism can occur simultaneously. Objective Our aim was to investigate the prevalence of hyperparathyroidism in PA. Patients We performed a case finding o… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
24
0
1

Year Published

2020
2020
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 16 publications
(25 citation statements)
references
References 42 publications
(62 reference statements)
0
24
0
1
Order By: Relevance
“…In a recent study, Asbach et al reported the prevalence of primary hyperparathyroidism was 1.2% in a retrospective series of 503 patients with PA, and was 2.1% in 141 prospective PA patients, higher than in normal subjects (2.33‰ in women, 0.85‰ in women). They also observed that secondary hyperparathyroidism was common in patients with PA (39,40). Meanwhile, Concistre et al reported the prevalence of primary hyperparathyroidism in patients with PA was 2.6% (8/306) (41).…”
Section: Primary Aldosteronism and Hyperparathyroidismmentioning
confidence: 99%
“…In a recent study, Asbach et al reported the prevalence of primary hyperparathyroidism was 1.2% in a retrospective series of 503 patients with PA, and was 2.1% in 141 prospective PA patients, higher than in normal subjects (2.33‰ in women, 0.85‰ in women). They also observed that secondary hyperparathyroidism was common in patients with PA (39,40). Meanwhile, Concistre et al reported the prevalence of primary hyperparathyroidism in patients with PA was 2.6% (8/306) (41).…”
Section: Primary Aldosteronism and Hyperparathyroidismmentioning
confidence: 99%
“…This is higher than the reported in previous studies, that described prevalences that varied between 1.2% and 2.6% [11][12]. However, it is di cult to know the real prevalence as most of the series were limited to the report of single cases, and the largest series reported included 503 cases of PA, but only 141 patients prospectively included [11]. Nevertheless, the association of PA and primary hyperparathyroidism does not seem to be explained only by chance, as several studies [4,8,13,20] have defended the existence of a bi-directional functional link between the adrenocortical zona glomerulosa and the parathyroid gland.…”
Section: Discussionmentioning
confidence: 69%
“…Thus, it would be expected that the combined secretion of aldosterone and iPTH would aggravate cardiovascular morbidity and mortality in patients with PA. However, few studies have evaluated this association [11][12][13][14][15] and the results about the improvement of the associated cardiovascular morbidity after parathyroidectomy are controversial, and some studies did not observe any improvement [14] [15]. Moreover, to the best of our knowledge no previous study has compared the prevalence and incidence of hyperparathyroidism in PA and essential hypertensive patients.…”
Section: Introductionmentioning
confidence: 99%
“…В когорте пациентов с ПГПТ получены противоречивые результаты в отношении изменения концентрации параметров РААС, а также уровня ПТГ при приеме препаратов, влияющих на активность данной системы регуляции АД [22,23]. Тем не менее представлены клинические случаи сочетанного развития ПГПТ и альдостеронпродуцирующей опухоли надпочечника [24][25][26], при этом предполагается, что гиперпаратиреоз и гиперальдостеронизм потенцируют патологические эффекты друг друга на сердечно-сосудистую систему [2,27].…”
Section: ââåäåíèåunclassified